Annex 1 is a key piece of legislation for pharmaceutical manufacturers to operate in Europe. Recent news that the legislation is set to be revised has led to many industry leaders contemplating what the updated documentation might state and questioning whether they’ll still be able to operate.
Christian Dunne, Head of Sterility Assurance at ChargePoint Technology, looks at what the industry can expect to see and how manufacturers can continue to meet the new standards when they come into effect.
Read the full article here
